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ABSTRACT
Laboratory processing pathways have a significant impact on the overall management of patients with sepsis. Retrieval and isolation of the suspected pathogen from a patient blood culture specimen is required for a definitive diagnosis of bacterial septicemia. Reference laboratories are high-volume facilities most often located some distance away from the collecting facility. Given the lengthy work up already required for blood culture pathogen analysis, reference laboratories must identify ways to optimize every step of the blood culture pathway in the effort to decrease turnaround time and mitigate lag time to final pathogen identification incurred by prolonged collection-to-incubation times. Rapid molecular diagnostic methods independent of culture results is an available potential solution. The focus of this paper is to consider published literature on the evaluation of rapid blood culture testing to identify its potential benefits and ultimately layout a properly developed implementation plan that integrates the Verigene microarray-based rapid blood culture testing system (Nanosphere, Northbrook, IL, USA) into the blood culture workflow at a high-volume reference laboratory. An increase in mortality rate is directly related to delays in reportable results for infections considered medical emergencies thus, in the case of sepsis, any delays prove significant when appropriate therapy is dependent on pathogen identification and susceptibility turnaround time (4, 5) . Retrieval and isolation of the suspected pathogen from a patient blood culture specimen is required for a definitive diagnosis of bacterial septicemia. This process can take between 1 and 3 days after a presumptive positive flag has been identified (5).
Laboratory processing pathways have a significant impact on the overall management of patients with sepsis and delays to appropriate patient care can be observed anywhere from collection to reporting (8) . Pre-analytical factors like whether a blood culture is processed in the same facility where bedside collection took place or processed at a core laboratory away from bedside collection location are important to consider when the concern for turnaround time is as urgent as is with blood culture testing. Core laboratories, also known as reference laboratories are high-volume facilities that process anywhere between 100,000 specimens a year to over 1,000,000 specimens a year and are most often located some distance away from the collecting facility (6) . Given the lengthy work up already required for blood culture pathogen analysis, reference laboratories must identify ways to optimize every step of the blood culture pathway in the effort to decrease turnaround time and mitigate delay time to final pathogen identification incurred by prolonged collection-to-incubation times.
While the need for rapid microbiology results was discussed in literature dating back to the 1980's, rapid molecular testing platforms within microbiology laboratories have only begun to be a norm during the last decade (8) . Culture-based methods to identify pathogens remain the gold standard and prove necessary as comprehensive susceptibility information is required for appropriate therapy however, results obtained from rapid molecular testing platforms, independent of culture, have recently been acknowledged as necessary (9) . The focus of this paper is to consider published literature on the evaluation of rapid blood culture testing to identify its potential benefits and ultimately layout a properly developed implementation plan that integrates the Verigene microarray-based rapid blood culture testing system (Nanosphere, Northbrook, IL, USA) into the blood culture workflow at a high-volume reference laboratory. Due to unforeseen proprietary issues the high-volume reference laboratory name and location will remain undisclosed.
Benefits to implementing rapid blood culture testing Most documented benefits to adopting rapid blood culture testing are centered around the clinical aspect of patient care. Separate studies performed by MacVane et al., and Perez et al., demonstrate a significant impact to effective therapy selection as well as a more rapid approach by providers to utilize narrow-spectrum antibiotics (11, 12) . This prompt de-escalation of antimicrobial therapy is relevant not only to hospitalized patient outcomes but also directly related to hospital costs. Documented analysis of patient hospital length of stay and total hospital cost between two controlled studies at one hospital, identified nearly $20,000 average reduction in cost when comparing pre-and post-rapid pathogen identification platform integration (12) . It is important to note that the aforementioned studies demonstrate maximum benefits are obtained when appropriate action is taken by antimicrobial stewardship programs in place (11, 12) . Time is of the essence when it comes to definitively diagnosing sepsis. Blood culture bottles should be delivered to the processing laboratory soon after collection to avoid instrument incubation loading delays and ultimately time to pathogen detection delays (13) . Pre-analytical delays incurred by processing blood cultures at a reference laboratory may inadvertently pose a risk to patient treatment by prolonging the time to detection of organisms. Although manufacturers specify collected blood culture bottles may be held at 25°C for up to 24 h prior to loading into a continuous-monitoring blood culture instrument without compromising results, a controlled study suggests temperature and holding time before incubation can lead to an increase in time to positive detection as well as a decrease in organism detection as a whole (13) . Rapid blood culture testing platforms offer clinically useful information on average 1.5-1.7 days sooner than the results obtained by conventional methods (11, 15) . If pre-analytical factors like specimen transport cannot be modified then the opportunity for improving turnaround times through testing platforms that provide rapid diagnostic results should be strongly considered.
Comparable assays: Verigene vs FilmArray
The main focus of this paper is to develop an implementation plan to integrate the Verigene assay into the positive blood culture workflow of a high-volume reference laboratory. Although a number of nucleic acid diagnostic assays are available for rapid pathogen detection directly from blood culture, the Verigene platform has been previously chosen by administrators and validated for use by research and development at the reference laboratory. Reasoning for choosing the Verigene platform over others on the market was not disclosed. In an effort to make an informed conclusion about the Verigene assay a brief comparison to FilmArray (BioFire Diagnostics, Salt Lake City, UT), a similar rapid blood culture identification assay, will be made. Both Verigene and
FilmArray are qualitative multiplexed testing platforms that use slightly different nucleic acid technologies to detect multiple pathogens and select genetic determinants directly from positive blood culture bottles (16) (17) (18) .
The Verigene molecular assay detects nucleic acid targets of the pathogens listed in Table 1 and accounting for 52% to 77% of bacterial sepsis (19) . It is an advantage to rapidly identify coagulase negative staphylococcus species (CNS) like S.epidermidis and S.lugdunensis because of their more recently understood roles as pathogens (19, 20) .
Verigene BC-GP and BC-GN combined offer the ability to detect 9 of the most common resistance markers including some of the most concerning carbapenamase resistance genes (Table1). Since the first Enterobacteriaciae carbapenemase resistant organism was identified in 1993 the concern to rapidly identify these multidrug resistant species has grown (21) . The FilmArray BCID assay does not offer detection for extended spectrum beta-lacatam (ESBL) resistance genes, however, it does detect one other gram-negative pathogen to species level that the Verigene BC-GN does not, Acinetobacter baumanii. This Acinetobacter sp. is recognized as a major drug-resistant organism implicated in nosocomial infections (16) .
Assay limitations exist for both platforms and a number of them have been compiled in Table 2 . The following limitations described, although not all inclusive, appear to show significant variability in performance and should be considered by laboratory scientists upon final result review. Steps in the pre-analytical phase cannot be addressed within the scope of this paper but it is important to acknowledge the average time of 8 hours that it takes for a blood culture to be loaded onto the incubation instrument from time of collection (Fig.2) .
The workup process for the current blood culture workflow follows the general principle of subculture, gram stain review, and gram stain result notification to appropriate provider. Emphasis is placed on prompt incubation of subculture media at optimal conditions (37°C/CO2) to allow adequate bacterial growth for analysis early enough on day two of blood culture positive workflow (Fig. 2) .
The evaluated reference laboratory operates on a 24-hour 3 shift system with groups of employees starting at various times: Shift 1 includes groups starting every hour between 6 AM and 10 AM; groups in Shift 2 start every hour between 2 PM and 4 PM (including a limited number starting at 3:30PM); and all employees on Shift 3 start at 10 PM. Scheduling priority is given to the blood culture assignment to avoid gaps between shifts that may potentially lead to unnecessary delays in processing blood culture positives. Moreover, two skilled bacteriologists are scheduled per shift. All shift 2) up to 6 hours of their assigned shift allowing the last two hours for post analytical documentation review of LIS documentation, slide archiving, and paper worksheet completion. The post-analytical steps are not included in Figure 2 nor Figure 4 as they do not affect the overall process of blood culture positive handling.
Although an advantage of using MALDI-TOF MS (Matrix assisted laser desorption ionization-time of flight mass spectrometry) for pathogen identification on day 2 of analysis exists, a review of the current blood culture workflow process highlights the prolonged amount of time it still takes for organism identification information to reach clinicians (Fig. 3) . Summing the average amount of time it takes to update a report with a pathogen ID obtained on MS, with the average time from collection to initial positive blood culture flag, it is clear that efforts to decrease the time to identification still requires improvement in order to prove beneficial to the patient treatment outcome (Table 3 ). Furthermore, this additional media to be added is dependent on gram stain morphology. Since supplemental media cannot be added until gram stain review is performed, incubation at the ideal 37°C/CO2 conditions is delayed. This process forces Modified blood culture work-up method: Verigene implementation The initiative to integrate rapid blood culture testing was seriously considered at the evaluated high-volume reference laboratory back in 2015. For undisclosed reasons, the implementation was never followed up. Per discussion with upper management overseeing research and development at the reference lab, interest in introducing the Verigene BC-GP assay into positive blood culture workflow processes exists and it is apparent that it will be more seriously considered upon laboratory expansion later this year. It is the goal of this section to introduce a modified blood culture workflow that integrates rapid blood culture testing for gram positive organisms and considers solutions to the aforementioned opportunities for improvement.
The modified workflow process, in contrast to the current method, puts emphasis on gram stain review and call notification over subculture to address the critical component of gram stain evaluation, as it relates to provider notification and initiation of rapid identification assay (Fig. 4) . Immediately after gram stain review, BC-GP panels will be set up for all gram-positive cocci in cluster, gram-positive cocci in pairs and/or chains, and any gram-positive rods isolated from aerobic blood culture bottles not previously identified by rapid assay (Fig. 5 ). During the 2 h BC-GP assay turnaround time, gram stain notification is performed per shift protocol, media is respectively organized/labeled, subculture in biohood is performed, and subcultures are appropriately incubated at optimal 37°C/CO2 conditions (Fig. 4 ). Since identification to species level will be obtained for the most common gram-positive blood culture pathogens (Table 1) on analytical day 1 (Fig. 4) the need for tube coagulase to rule out Staphylococcus aureus and disk diffusion screen plates specific for gram-positive pathogens is eliminated. Additionally, when the bacteriologist is ready to go into the biohood for subculture, all necessary media will be labeled and ready for inoculation.
Upon incubation of first "pull" subcultures, the bacteriologist will ensure Blood Culture Positive Worksheet is filled in (Appendix A) and necessary LIS documentation has been verified before continuing on with the process. Moreover, before gram stain reviews are performed on subsequent "pulls" or shortly thereafter, one of the two scheduled bacteriologists should monitor the Verigene instrument (assigned as an alternate workflow pathway and indicated as a dotted line on Figure 4 ) for pending BC- 
FIGURE 4: PROPOSED WORKFLOW
GP results and document any completed results in LIS per information outlined in Figure   6 and Table 4 .
The proposed process map includes two additional steps in analytical day 1, not present in the current process map, in an effort to address the need for continuous workflow and promote a structured endorsement of work between shifts. Additionally, changes to analytical day 2 were required to account for rapid identification performed.
At the beginning of a shift, the scheduled bacteriologists must acknowledge receipt of any work from the previous shift and will assume responsibility to complete any additional tasks required as outlined on "End of shift protocol" (Figure 4 ).
Conversely, one hour before end of shift all flagged blood culture positives must be 
FIGURE 5: DECISION CHART FOR BC-GP SET UP
Anticipated workflow benefits and challenges Essentially, the BC-GP ID assay is not meant to take the place of any of the current steps of the workflow process thus as expected, when comparing process maps for the current and proposed method, the proposed method appears more cumbersome. Benefits to workflow processes are not as obvious as one might presume but they do exist. 
FIGURE 6: DECISION CHART FOR RELEASING RESULTS
Although it is clear that additional steps are required to set up a supplementary method of identification on analytical day 1, hands on time for the Verigene BC-GP is less than 5 minutes (16, 17) . Moreover, the proposed workflow, outlines rapid ID to be limited to aerobic specimens without documented previous history hence anticipating a minor interruption of overall workflow (Fig. 5) . These additional steps required in the analytical phase of day 1 will prove beneficial to the workflow in the analytical phase of day 2 in that, isolates with rapid ID results should require minimal phenotypic bacteriologist review before susceptibility workup can be initiated. A retrospective look at organism identification, for 108 randomly selected non-duplicate positive blood samples, demonstrated that over 80% of organisms identified by conventional method could have benefited from rapid identification on analytical day 1 (Table5). Methodist Hospital, found that improving positive blood culture "pull" time can significantly decrease total processing time (27) . Minor changes to the blood culture work up process at Houston Methodist Hospital lab improved the blood culture "pull" times from 38 m to 8 m (27) . It may be arguable that 30 minutes is not significant enough to impact patient care but, when mortality rate is increased by turn-around time delays and time for definitive pathogen identification is prolonged by the unavoidable pre-analytical aspect of processing a blood culture specimen at a reference laboratory, the impact can be regarded as more substantial.
Limitations to the BC-GP assay causing discrepancies in reportable results must be addressed as additional challenges ( Table 2 ). The proposed workflow process has integrated decision algorithms for both analytical day 1 and analytical day 2 that direct the bacteriologist to reject or confirm BC-GP assay results respectively depending on internal control results and phenotypic characteristics (Fig. 5, Fig. 3 ). LIS reporting considerations must be taken to acknowledge the risk of false-positive results due to cross-reactivity between identifiable targets as well as due to its documented poor performance in identifying organisms in polymicrobial cultures (17) . A report of, "Presumptive (insert organism and resistance marker if any) identification obtained by rapid ID method; culture results to follow.", will be issued on the analytical day 1 of work up contingent on internal control results. Including "Presumptive" in the initial preliminary report will allow for confirmation of results on analytical day 2.
Furthermore, as detailed in Figure 5 , if controls are "not detected" or a "no call" result is obtained, repeat testing will not be performed and a result of "Rapid ID unsuccessful; culture in progress." will be reported.
Conclusion and outlook
It is impossible to foresee all workflow challenges that may arise when implementing a new platform thus, the proposed workflow for the integration of the Verigene BC-GP assay into the established blood-culture work up method at the evaluated high-volume reference laboratory, is set forth as an initial framework to build upon. Even if plans to integrate the Verigene assay are not fulfilled, there are a number of benefits to visually mapping out the current blood culture positive pathway as it has been done here. Observations to specific potential problem areas were made in this process analysis and suggestions for improvement presented can be a topic for further discussion at department meetings.
My recommendation for the high-volume reference laboratory under evaluation is to try the proposed gram stain suggestions and presented continuous workflow steps before moving forward with integrating a rapid blood culture identification test. This may prove beneficial in the long run such that one test of change carried out in small scale can help anticipate potential problems and will allow staff to more easily adapt to upcoming changes. A reasonable approach would be to direct one of two scheduled bacteriologists to adhere to the proposed continuous workflow process while the other follows established protocol to allow comparisons to be made side by side.
The opportunity to integrate molecular diagnostics into microbiology testing, at the evaluated high-volume reference laboratory, comes with the need for expansion as 22 testing volumes continue to increase. With this opportunity to integrate exciting new platforms also comes the opportunity to evaluate workflow processes with the end goal of optimizing a pathway that is known to have a big impact on patient care. Clinical microbiology laboratories must not forget the role they play in the larger scheme of patient care and look for ways to evolve with the advancement of molecular technology.
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